Q-omics provides the consensus-scored CEP83-DT profile across patient tissues and cancer cell-line models. CEP83-DT expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, CEP83-DT is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CEP83-DT RNA expression shows 19,958 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, KIRC, and ACC as cancer lineages where CEP83-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEP83-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEP83-DT survival associations across molecular data types. CEP83-DT RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEP83-DT RNA expression–survival associations across cancer types. High CEP83-DT expression shows unfavorable associations in MESO, ACC, KICH and LIHC, but favorable associations in UCS and PAAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for CEP83-DT RNA expression.
This table summarizes CEP83-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CEP83-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEP83-DT shows lower tumor expression in KIRC, THCA and KICH and higher tumor expression in HNSC, LIHC and BLCA. The KIRC box plot shows higher CEP83-DT RNA expression in normal versus tumor tissue (log2 FC = −0.522, t-test p < 0.001).
This table shows molecular features associated with CEP83-DT in patient tissues and cancer cell lines. In patient samples, CEP83-DT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
